G. V. Prasad is the CEO of Dr. Reddy's Laboratories. Prasad is based in India. Prasad was born in 1960 and educated at Illinois Institute of Technology and Purdue University.
Latest on The Wire
See all →Dr Reddys shares tumble nearly 9 pc to hit 52-week low post-Q1 earnings announcement
Jul 23 · via Daily ExcelsiorDr Reddy’s Q1 profit falls 69% as semaglutide issue and lenalidomide loss hit earnings
Jul 22 · via BusinessLineNikhil Kamath Brings Together Pharma Veterans to Decode Indias Evolving Healthcare Landscape
Jun 19 · via TheWire.inFrom generics to innovation: India pharma’s next growth story takes centre stage on Nikhil Kamath’s WTF
Jun 19 · via Fortune India
Recent developments
AI summary of recent coverageRecent coverage of G. V. Prasad has focused on Dr. Reddy's Laboratories facing significant earnings pressures, with the company reporting a 69 percent decline in Q1 profit amid challenges including semaglutide supply issues and loss of lenalidomide exclusivity, leading to a sharp decline in share price. Coverage has also highlighted Prasad's strategic vision for the company's pivot toward biosimilars and innovation while maintaining generics as a core business, including discussions around a competitive generic version of a weight loss drug intended for approval in Canada. Beyond operational matters, recent profiles have examined Prasad's philosophy on business leadership and the role of Indian pharmaceutical companies in driving innovation within the healthcare landscape.
Summarized from the headlines below; see each source for the full story.
Key Facts
Source: Wikidata ↗- Born
- 1960
- Citizenship
- India
- Education
- Illinois Institute of Technology, Purdue University
Our coverage
On CEOInsider
No feature yet. When we publish a feature, interview or cover story on G. V. Prasad, it will appear here — and tie into the news timeline.
12 stories tracked
In the News
- Daily Excelsior·
Dr Reddys shares tumble nearly 9 pc to hit 52-week low post-Q1 earnings announcement
- BusinessLine·
Dr Reddy’s Q1 profit falls 69% as semaglutide issue and lenalidomide loss hit earnings
- TheWire.in·
Nikhil Kamath Brings Together Pharma Veterans to Decode Indias Evolving Healthcare Landscape
- Fortune India·
From generics to innovation: India pharma’s next growth story takes centre stage on Nikhil Kamath’s WTF
- Telangana Today·
Dr Reddy’s Q4 profit falls 86 per cent on weak North America sales
- Forbes India·
Money is an outcome, not the goal: Dr Reddy’s GV Prasad
- Forbes·
G.V. Prasad
- The Economic Times·
Biosimilars & innovation are Dr. Reddy’s growth pill: Generics to remain core business, says co-Chairman &
- CNBC TV18·
Dr Reddy’s close to Canada approval for generic weight loss drug: GV Prasad
- Reuters·
Dr Reddy’s says Wegovy copycat to be priced competitively, with 50–60% discounts feasible
- Investment Reports·
G. V. Prasad, Dr. Reddy’s Laboratories
- McKinsey & Company·
India as a pharma innovation hub: An interview with Dr. Reddy’s G. V. Prasad
G. V. Prasad: FAQ
- What company does G. V. Prasad lead?
- G. V. Prasad is CEO of Dr. Reddy's Laboratories.
- Where was G. V. Prasad educated?
- G. V. Prasad studied at Illinois Institute of Technology, Purdue University.